Incyte Corporation is a biopharmaceutical firm that discovers, develops, and sells therapeutic drugs across the United States, Europe, Canada, and Japan. The company markets treatments for blood cancers and immune disorders, including JAKAFI for myelofibrosis and related conditions, ICLUSIG for certain leukemias, MONJUVI/MINJUVI for lymphomas, and NIKTIMVO for chronic graft-versus-host disease, alongside several other approved and investigational medications targeting myeloproliferative neoplasms, solid tumors, and dermatological conditions. Incyte distributes its products through specialty pharmacies, retail pharmacies, hospital pharmacies, and wholesalers, and maintains research partnerships with companies including Novartis, Lilly, and Syndax.

entry readiness 23 · NOT READY · exit proximity 0

Value area 109.96–129.37 · 31% of 120d volume overhead · moderate overhead